RNA Therapies

CUSTOMER CHALLENGE

The utility of RNA in biopharmaceuticals has been successfully demonstrated across a range of applications, from modulation of cellular function in RNA interference to guiding RNA in CRISPR based gene editing. To date, the most successful application of RNA technologies has been in the rapid development and delivery of a vaccine for COVID-19, a case study in the speed at which development can occur using RNA technologies. However, this potential for development speed is not matched by traditional characterization and biosafety testing and approaches, as this testing can take months.

PATHOQUEST SOLUTION

PathoQuest can help characterize, QC and release your RNA therapies across the manufacturing journey

DISCOVERY

PRE-CLINICAL

PHASE 1

PHASE 2

PHASE 3

MARKET

Cell selection/characterization of modifications on/off target

Cell line characterization – MCB, WCB, End of Production

In-process testing – bulk harvest lot release, biosafety and viral testing

Final product release testing – identity testing

Raw material screening

Investigatory support

PATHOQUEST SOLUTION

PathoQuest can help characterize, QC and release your RNA therapies across the manufacturing journey

OUR EXPERTISE

PathoQuest’s expert GMP level NGS services are ideal to meet the needs of RNA therapy developers. NGS is uniquely placed to enable characterization and identification of the RNA product, such as its ability to identify ultra-rare sequence variants, which can be problematic.

PathoQuest is the leader in both application innovation and acceptance of NGS within the biosafety and characterization field, as demonstrated by our active participation in industry groups and our peer reviewed publication record. You can have the highest confidence in the results, as our NGS assays are backed by expert bioinformatic support, meaning you are not left to interpret results by yourself.

CHALLENGES SOLVED

PathoQuest addresses the key challenges you face in manufacturing and releasing your RNA therapy by addressing key concerns:

  • Faster cell line development and selection with deeper genetic insights
  • De-risking your manufacturing process by rapidly screening critical raw materials
  • Reducing the characterization bottleneck and giving you confidence in the quality of your RNA sequence
  • Meeting corporate 3Rs ethical objectives by removing animal models

Modalities

mAbs and Recombinants

Bacterial and mammalian produced proteins, hormones and peptides

READ MORE

Viral Vectors

Viral gene delivery, oncolytic and immunotherapy including manufacturing plasmids

READ MORE

Cell Therapies

Including gene modified, or unmodified stem cell therapies, allogeneic or autologous

READ MORE

Vaccines

Inactivated, live-attenuated, recombinant, RNA and viral vector products

READ MORE

RNA

Immunotherapies, antiviral, vaccines, RNAi and CRISPR based gene editing

READ MORE

Cultivated Meat

Engineered cells and tissues cultured in more ethical in vitro environments

READ MORE

Contact us

U.S.

+1 484 212 9360

466 Devon Park Dr
Wayne, PA 19087
United States

Sign up for our latest news

France

+33 (0)1 70 82 17 90

Biopark -Bâtiment B,
11, rue Watt
75013 Paris, France

How can PathoQuest help?

Name(Required)
This field is for validation purposes and should be left unchanged.

U.S.

+1 484 212 9360

466 Devon Park Dr
Wayne, PA 19087
United States

France

+33 (0)1 70 82 17 90

Biopark -Bâtiment B,
11, rue Watt
75013 Paris, France

How can PathoQuest help?

Name(Required)
This field is for validation purposes and should be left unchanged.

Sign up for our latest news